Maison Capital

Investor type Private Equity Firm


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 36
Average round size
The average size of a deal this fund participated in
Portfolio companies 31
Rounds per year 2.00
Lead investments 7
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 3
Key employees 8

Areas of investment

  • Health Care
  • Biotechnology
  • Artificial Intelligence
  • Medical
  • Food and Beverage

In 2004 was created Maison Capital, which is appeared as VC. The main office of represented VC is situated in the Grand Cayman. The fund was located in North America if to be more exact in Cayman Islands.

For fund there is no match between the location of its establishment and the land of its numerous investments - China. We can highlight the next thriving fund investment areas, such as Food Delivery, 3D Technology. Among the most popular portfolio startups of the fund, we may highlight NASN Automotive Electronics, iXiandou, SinoUnited Health Clinic. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little.

The important activity for fund was in 2019. Considering the real fund results, this VC is 34 percentage points more often commits exit comparing to other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in 2-6 deals per year.

Besides them, we counted 8 critical employees of this fund in our database.

The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the Maison Capital, startups are often financed by ZhenFund, Qiming Venture Partners, Matrix Partners China. The meaningful sponsors for the fund in investment in the same round are Qiming Venture Partners, Seas Capital, Matrix Partners China. In the next rounds fund is usually obtained by Qiming Venture Partners, Yunyi Capital, U.S.-China Green Fund.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Maison Capital:
Typical Co-investors
Maison Capital is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Maison Capital:
There are no funds here. If we find new data, we will add it here.

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Enxi Village

Food and Beverage
21 Apr 2022 Shenzhen, Guangdong, China


Digital Marketing
Information Services
Information Technology
$15M01 Mar 2022 Futian District, Guangdong Province, China

YUSUR Technology

21 Dec 2021 Beijing, Beijing, China


Artificial Intelligence
$15M19 Nov 2021 Shenzhen, Guangdong, China

Insilico Medicine

Artificial Intelligence
Health Care
$255M22 Jun 2021 Hong Kong Island, Hong Kong, China


$75M14 Jun 2021 Paris, Ile-de-France, France

Yongpu Kafei

$7M10 Jun 2021 Shanghai, Shanghai, China

Health Care
$105M13 May 2021 Shanghai, China

Xuan's Mom

$16M27 Apr 2021 Jiangmen, Guangdong Province, China
Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus

– Insilico Medicine announced that it has closed a $255m Series C.
– The financing led by Warburg Pincus, and participated by current investors including Qiming Venture Partners, Pavilion Capital, Eight Roads Ventures, Lilly Asia Ventures, Sinovation Ventures, BOLD Capital Partners, Formic Ventures, Baidu Ventures, and new investors including CPE, OrbiMed, Mirae Asset Capital, B Capital Group, Deerfield Management, Maison Capital, Lake Bleu Capital, President International Development Corporation, Sequoia Capital China and Sage Partners.
– The financing will be used to progress Insilico Medicine’s current therapeutic programs into human clinical trials, initiate multiple new programs for novel and difficult targets, and further develop its AI and drug discovery capabilities.

HiFiBiO Therapeutics Closes $75M Series D

– HiFiBiO Therapeutics, a biotechnology company with expertise in immune modulation and drug intelligent science, announced the completion of an oversubscribed $75M Series D financing round.
– The funding was led by the new investor Mirae Asset Financial Group.
B Capital Group, Sherpa, Maison Capital, Trinity Innovation Fund, Grand Mount, and HKSTP Venture Fund also participated in this round.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Maison Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: